跳至主要内容
临床试验/NCT03901183
NCT03901183已完成不适用

Plant-based Nutrition for Patients With Cardiovascular Risk Factors - a Randomized Controlled Trial

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2019年5月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
70
试验地点
2
主要终点
Change of baseline Composite Score for Metabolic Syndrom (Standardizing Physiological Composite Risk Endpoints (SCORE)) at 2 months

研究概览

简要总结

Plant-based nutrition may have positive effects on chronic diseases such as cardiovascular or metabolic disorders. This study investigates the effects of a 8 week plant-based diet for patients with metabolic syndrom and cardiovascular risk factors.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Blood pressure > 140 mmHg systolic and/or > 90 mmHg diastolic, in case of medication also increased values > 140 mmHg systolic and/or > 90 mmHg diastolic needed
  • Adipositas with a waist circumference of > 94 cm in men and > 80 cm in women
  • A non-vegetarian diet in the past 6 months (at least 4x meat and/or meat products per week, at least 5x dairy products per week)
  • No fasting, no specific diet or change of diet in the last 2 months
  • Weight stable over the last two months (+- 3 kg)
  • Medication unchanged for at least one month
  • No fasting, no change of diet in the last 2 months

排除标准

  • Poor general condition
  • Coronary heart disease
  • Diabetes mellitus Type I
  • Cerebrovascular diseases
  • Severe mental illness
  • Severe acute or chronic comorbidity
  • Pregnancy and lactation or planned pregnancy in the next 6 months
  • Eating disorder
  • Max. 2 beers 0,5l or 2 wines 0,2l per day
  • No alcohol abstinence 48 hours before blood samples possible
  • Max. 5 cigarettes/day
  • Medicine that affect weight
  • Antibiotics within the last 6 months
  • Major surgery <6 months prior to randomization
  • BMI > 40 kg/m2
  • Existing vegetarian or plant-based diet
  • Bariatric surgery (obesity surgery)
  • Simultaneous participation in another clinical trial
  • Participation in a clinical trial within the last 3 months prior to inclusion in the study
  • Lack of consent to participate in the study

结局指标

主要结局

Change of baseline Composite Score for Metabolic Syndrom (Standardizing Physiological Composite Risk Endpoints (SCORE)) at 2 months

时间窗: Date of inclusion (baseline), after 8 weeks

Composite score including waist wircumference, blood pressure, fasting blood glucose, tryglycerids, HDL-cholesterin Range 0-100, lower score meaning a better outcome

次要结局

  • Bio-electrical Impedance Analysis (BIA)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Change from baseline systolic blood pressure at 2 months(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Blood lipids(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Ferritin (µg/l)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Holotranscobalamin (pmol/L)(Date of inclusion (baseline), after 16 weeks)
  • Quality of Life questionnaire (WHO-5)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • General Self-efficacy Short Scale (ASKU)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Body Mass Index (kg/m2)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Bio-electrical Impedance analysis (BIA)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Fructosamin (µmol/l)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Liver enzymes(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Folic acid (ng/ml)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Complete Blood Count(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Trimethylamine N-oxide (mg/dl)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Change from baseline diastolic blood pressure at 2 months(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Fasting glucose (mmol/l)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Glycated hemoglobin (HbA1c) (%)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Uric Acid (mg/dl)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Stress questionnaire (Cohen Perceived Stress Scale, CPSS)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Waist circumference (cm)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Flourishing Scale (FS-D)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Insulin (µU/ml)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Homeostatic model assessment (HOMA-IR)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Zerssen symptom list (B-LR and B-LR')(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Wrist Circumference (cm)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Ambulatory Blood Pressure Monitoring (ABPM)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Hospital Anxiety and Depression Scale (HADS)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Medical Outcomes Study Short Form (MOS SF-12)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Intuitive Eating Scale 2 (IES-2)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • International Physical Activity Questionnaire (IPAQ )(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Medication intake(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Gut microbiome(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Blood Oxygenization(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Body weight (kg)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Daily nutrition protocol(Daily throughout the entire survey period)
  • Dietary Behaviour(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Heart Rate (HR)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Heart Rate Variability (HRV)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Number of Steps per 24 hours(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of inflammatory oral conditions(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of teeth related conditions(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of Oral Fluids(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of periodontal status(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Cardio Vascular Risc Profile(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Skin Temperature(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Interbeat Interval (IBI)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Blood Volume Pulse(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Electrodermal Activity (Galvanic Skin Response)(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Respiration Rate(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Sociodemographic Measurements(Date of inclusion (baseline))
  • Oral Health Qualitative Interviews(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of periodontal attachment level(Date of inclusion (baseline), after 8 weeks, after 16 weeks)
  • Evaluation of oral hygiene(Date of inclusion (baseline), after 8 weeks, after 16 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andreas Michalsen

Prof. Dr. med.

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验